Krystal Biotech, Inc. KRYS Accrued preclinical and clinical expenses
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept krys:AccruedPreclinicalAndClinicalExpenses.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accrued preclinical and clinical expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accrued preclinical and clinical expenses?
- Krystal Biotech, Inc. (KRYS) reported accrued preclinical and clinical expenses of $3.8M in Q1 2026.
- How has Krystal Biotech, Inc.'s accrued preclinical and clinical expenses changed year-over-year?
- Krystal Biotech, Inc.'s accrued preclinical and clinical expenses increased by 28.4% year-over-year, from $2.96M to $3.8M.
- What is the long-term trend for Krystal Biotech, Inc.'s accrued preclinical and clinical expenses?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s accrued preclinical and clinical expenses has grown at a 21.9% compound annual growth rate (CAGR), from $1.74M to $4.67M.